Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

INO Inovio Pharmaceuticals, Inc.
$1.25 -2.34% -0.03
Notify me if price changes either direction
Interactive Brokers Logotype

Buy INO stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 129.2M
Enterprise value 100.6M
Trailing PE -0.68784530650186
Forward PE -2.840909
PEG Ratio 0.0077701043882618
Enterprise to EBITDA -1.291
Enterprise to revenue 1539.1835697779
Price to book MRQ 23.584906
Price to sales TTM 1977.9761718929

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 65343
EBITDA -77932296
Diluted EPS TTM -1.03
Total Cash (MRQ) 36.7M
Current ratio (MRQ) 1
Operating Cash Flow (TTM) -80582584

INO trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent INO News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.